152 related articles for article (PubMed ID: 26525859)
1. Trends in PET Scan Usage for Imaging of Patients Diagnosed With Nonmetastatic Urologic Cancer.
Adejoro O; Alishahi A; Soubra A; Konety B
Clin Genitourin Cancer; 2016 Feb; 14(1):38-47.e1. PubMed ID: 26525859
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography in urologic oncology.
Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
[TBL] [Abstract][Full Text] [Related]
3. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
5. Variation in positron emission tomography use after colon cancer resection.
Bailey CE; Hu CY; You YN; Kaur H; Ernst RD; Chang GJ
J Oncol Pract; 2015 May; 11(3):e363-72. PubMed ID: 25852143
[TBL] [Abstract][Full Text] [Related]
6. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; Courbon F; Edeline V; Helal BO; Rossi D; Villers A; ; ; ; ; ; ; ;
Bull Cancer; 2006 Dec; 93(12):1228-32. PubMed ID: 17191352
[No Abstract] [Full Text] [Related]
7. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
8. PET in prostate and bladder tumors.
Lee ST; Lawrentschuk N; Scott AM
Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography in uro-oncology.
Hain SF
Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
[TBL] [Abstract][Full Text] [Related]
10. Advances in Imaging in Prostate and Bladder Cancer.
Srivastava A; Douglass LM; Chernyak V; Watts KL
Curr Urol Rep; 2017 Sep; 18(9):69. PubMed ID: 28718164
[TBL] [Abstract][Full Text] [Related]
11. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
[TBL] [Abstract][Full Text] [Related]
12. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
13. Trends in imaging after diagnosis of thyroid cancer.
Wiebel JL; Banerjee M; Muenz DG; Worden FP; Haymart MR
Cancer; 2015 May; 121(9):1387-94. PubMed ID: 25565063
[TBL] [Abstract][Full Text] [Related]
14. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
15. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis.
Canter D; Egleston B; Wong YN; Smaldone MC; Simhan J; Greenberg RE; Uzzo RG; Kutikov A
Urol Oncol; 2013 Aug; 31(6):866-70. PubMed ID: 21906968
[TBL] [Abstract][Full Text] [Related]
16. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
Bouchelouche K; Oehr P
J Urol; 2008 Jan; 179(1):34-45. PubMed ID: 17997425
[TBL] [Abstract][Full Text] [Related]
18. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
[TBL] [Abstract][Full Text] [Related]
19. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
[No Abstract] [Full Text] [Related]
20. [Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer].
Kanda T; Nakagomi K; Goto S; Torizuka T
Hinyokika Kiyo; 2008 May; 54(5):325-32. PubMed ID: 18546855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
